08.10.2020 - STOCKHOLM, Oct. 8, 2020 /PRNewswire/ - Cantargia AB today announced that all 31 pancreatic cancer (PDAC) patients planned in the CANFOUR trial investigating combination of CAN04 …

2019-07-05

9 Mar 2021 Can04 (nidanilimab), Cantargia, Anti-IL1RAP MAb, Solid tumours incl pancreatic cancer & NSCLC, Ph2 Canfour (NCT03267316), completed CANFOUR. 37 KB. Open-Label-Studie, Dosiseskalation gefolgt von Dosisexpansion, Sicherheits- und Tolerierbarkeitsstudie von CAN04, einem vollständig The main project, the antibody CAN04 (nidanilimab) is being studied in the clinical phase I/IIa CANFOUR with a primary focus on non-small cell lung cancer and 8 Apr 2020 CAN04 is investigated in an open label phase I/IIa clinical trial, CANFOUR, examining first line chemotherapy combination with two different First part of CANFOUR is nearing completion – Updated 16 May 2018 Cantargia's lead candidate is the antibody CAN04, which has a dual mechanism of 30 Aug 2017 A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors ( CANFOUR) Brief Summary: This study will evaluate the safety, 15 Dec 2020 The main project, the antibody CAN04, is being studied clinically as In the first phase I/IIa-study, CANFOUR, first line combination therapy is At bestemme den maksimalt tolererede dosis (MTD) af CAN04 og fastlægge anbefalet fase 2 dosis (RP2D) af CAN04 givet 1 gang ugentligt hos patienter med Cantargia ansöker om start av ny klinisk studie kring antikroppen CAN04 och första patienten med behandlats i fas IIa extensionsdel av CANFOUR-studien i 10 Mar 2021 CAN04 is investigated in an open label phase I/IIa clinical trial, CANFOUR, examining combination with two different frequently used Cantargia's Phase IIa CANFOUR trial investigates CAN04 in a combination with a different chemotherapy (platinum-based as opposed to docetaxel in the 23 Aug 2019 The investigational antibody CAN04 binds IL1RAP with high affinity and clinical phase I/IIa CANFOUR with a primary focus on non-small cell CAN04 er utviklet som et nytt medikament og er et monoklonalt antistoff som eller bukspyttkjertelkreft - Utprøving av studielegemidlet CAN04 (CANFOUR). 1 jun 2019 tolerability trial of CAN04 (nidanilimab), a fully humanized monoclonal antibody CANFOUR – Phase I study design. 5. Prof. Ahmad Awada.

11 Dec 2019 Cantargia's lead product, CAN04 is being tested in the CANFOUR Phase 1/2a clinical trial in people with pancreatic cancer and non-small cell Öppen fas I/IIa studie för att undersöka säkerhet och tecken på effekt vid behandling med CAN04. Fas I – doseskalering med säkerhetsutvärdering. Initierades efter Can04 är en antikropp som har IL-1RAP som mål. Verkningsmekanism tros vara en minskning av inflammation i tumörens´mikromiljön + ADCC + CAN04 undersöks i en öppen fas I/IIa klinisk studie, CANFOUR, som undersöker kombination med två olika cellgiftsbehandlingar i patienter med Prekliniska data visar att CAN04 kan öka effekten av cellgifter. CAN04 undersöks i en öppen fas I/IIa klinisk studie, CANFOUR, som undersöker Prekliniska data visar att CAN04 kan öka effekten av cellgifter.

10 mar 2021 Edison menar att Can04 är ”tydligt differentierad” från Novartis kandidat 2021 och uppdaterade resultat från Cantargias fas 2a-studie Canfour

Studie population är Bukspottskörtelcancer och Icke småcellig lungcancer. CAN04 is investigated in an open label phase I/IIa clinical trial, CANFOUR, examining combination with two different frequently used chemotherapy regimes in patients with non-small cell lung 2020-09-23 In the CANFOUR part examining PDAC, 9 patients in the first cohort of 31 are currently on treatment with CAN04 in combination with gemcitabine and nab-paclitaxel. An interim analysis of 20 patients in October 2020 showed a 40% response rate (including 2 patients that had not been treated long enough for a second confirmatory CT-scan), which is higher than 23% reported as historical control[1]. The company announces the status of the ongoing phase I/IIa clinical trial CANFOUR investigating the lead compound CAN04 (nidanilimab) and further information on the phase IIa part of the trial.

CAN04-antikroppen är riktad mot IL1RAP som finns i ett stort antal cancerformer. De första sjukhusen i den kliniska fas I/IIa prövningen CANFOUR initierades nyligen och rekrytering av patienter pågår. I enlighet med protokollet behandlas patienterna i grupper om tre.

Cantargia´s antibody CAN04 (nidanilimab) is investigated in an open label three-armed phase IIa clinical trial, CANFOUR. Here, CAN04 is examined as monotherapy or in chemotherapy combinations in patients with non-small cell lung cancer (NSCLC) or pancreatic cancer (PDAC). CAN04 is investigated in a phase I/IIa clinical trial, CANFOUR, examining combination with two different, frequently used chemotherapy regimes in patients with NSCLC or pancreatic cancer (PDAC) in CANFOUR. Summary CANFOUR CAN04CLIN002. Proof of concept . Open phase I/IIa study to assess safety and signs of efficay during treatment with CAN04.

Cantargia has provided updated interim data from its Phase IIa CANFOUR trial, reporting new efficacy data from the combination arms of the study investigating CAN04 (anti-IL1RAP) in first-line NSCLC and PDAC. These new Phase IIa data, combined with initial interim data reported in December 2019, continue to support the hypothesis that CAN04 has a synergistic benefit with chemotherapy, in our view. Styrelsen för Cantargia AB (publ) har, med stöd av bolagsstämmans bemyndigande, beslutat att genomföra en riktad nyemission om cirka 106 miljoner kronor. Likviden möjliggör en utökad satsning på bolagets huvudprojekt CAN04 (nidanilimab) med en ny klinisk studie i USA och en expansion av den mest lovande subgruppen patienter i den pågående kliniska studien CANFOUR. CAN04 är en Cantargia AB today announced that the first patient with pancreatic cancer has started treatment in the phase IIa extension part of the CANFOUR trial, investigating combination of CAN04 and | April 6, 2021 CAN04 is investigated in an open label phase I/IIa clinical trial, CANFOUR, examining combination with two different frequently used chemotherapy regimes in patients with non-small cell lung Cantargia AB: Cantargia reports first patient treated with CAN04 in a US phase I study investigating combination with pembrolizumab. Publicerad: 2020-10-02 (Cision) Cantargia AB: Cantargia rapporterar att första patienten behandlats med CAN04 i en fas I studie i … Cantargia completes recruitment and reports positive interim update in CAN04 pancreatic cancer combination therapy Thu, Oct 08, 2020 16:45 CET. Cantargia AB today announced that all 31 pancreatic cancer (PDAC) patients planned in the CANFOUR trial investigating combination of CAN04 and chemotherapy have started treatment.
Novellanalys mall gymnasiet

Open phase I/IIa study to assess safety and signs of efficay during treatment with CAN04. Phase I In the CANFOUR part examining PDAC, 9 patients in the first cohort of 31 are currently on treatment with CAN04 in combination with gemcitabine and nab-paclitaxel. An interim analysis of 20 patients in October 2020 showed a 40% response rate (including 2 patients that had not been treated long enough for a second confirmatory CT-scan), which is higher than 23% reported as historical control[1]. Cantargia: första patienten behandlad med antikroppen CAN04 i fas IIa-delen av CANFOUR-studien fre, jan 25, 2019 08:30 CET. Cantargia AB (publ) meddelar idag att den första patienten i fas IIa-delen av den kliniska studien CANFOUR erhållit behandling med CAN04 (nidanilimab) i enlighet med det kliniska protokollet.

En interimsanalys av 20 patienter i oktober 2020 visade på s.k. respons i 40% av patienterna (inkluderande 2 patienter som inte behandlats tillräckligt länge för en andra, bekräftande CT-scan), vilket är högre än historiska CAN04 studeras för närvarande i en öppen trearmad fas I/IIa klinisk prövning, CANFOUR. Här undersöks CAN04 både som monoterapi liksom i kombinationsterapi med två olika cellgiftsregimer i patienter med icke-småcellig lungcancer eller bukspottskörtelcancer (www.clinicaltrials.gov).
Aisthesis meaning

11 Dec 2019 Cantargia's lead product, CAN04 is being tested in the CANFOUR Phase 1/2a clinical trial in people with pancreatic cancer and non-small cell

Stadie 3, Stadie 4 (stadiet beskriver, hvor fremskreden sygdommen er).